EUCTR2009-011883-12-EE进行中（未招募）不适用
A Phase 2 Study for Transdermal Application of Teriparatide
Elli Lilly and Company0 个研究点目标入组 233 人开始时间: 2009年7月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 233
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patients are eligible to be included in the study only if they meet all of the following criteria:
- •[1]Ambulatory, postmenopausal women aged 45 to 85 years inclusive at the time of entry into the trial, whose last menstrual period occurred at least 2 years prior to entry into the trial. Women below the age of 55 years in whom a bilateral oophorectomy cannot clearly be documented must have their postmenopausal status confirmed by a serum follicle stimulating hormone (FSH) level of >30 IU/L and serum estradiol level of <20 pg/ml or <73 pmol/L.
- •[2]Centrally confirmed lumbar spine or femoral neck BMD T-score of =2.5 as measured by DXA. Absolute values should be used for assessing BMD and are as follows:
- •Skeletal Site BMD Absolute Value (g/cm2)
- •(T-score <-2.5)
- •Hologic Lunar
- •Lumbar Spine (L1-L4)<_0.772<-0.872
- •Femoral Neck <_0.558<_0.691
- •[3]Three of 4 vertebrae, L1 through L4, must be evaluable for BMD scoring, as measured by DXA.
- •[4]Free of severe or chronically disabling conditions other than osteoporosis (for example, uncontrolled diabetes or diabetes with significant renal, vascular, neurologic, or ophthalmic complications).
- •[5]Able to use a pen-type injection delivery system satisfactorily in the opinion of the investigator, or with the help of a family member or caregiver who can meet daily with the patient and is willing to be trained on and use the pen-injector on a daily basis.
- •[6]Able to use the ViaDerm Teriparatide System satisfactorily in the opinion of the investigator, or with the help of a family member or caregiver who can meet daily with the patient and is willing to be trained on and use the ViaDerm Teriparatide System on a daily basis.
- •[7]Without language barrier, cooperative, expected to return for all follow-up procedures, and have given informed consent after being informed of the risks, medications, and procedures to be used in the study.
- •[8]Able to be reached by telephone for follow-up contact between visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 168
排除标准
- •[1] Abnormal laboratory values for albumin and alkaline phosphatase (normal range as defined by the central laboratory), except for clinically insignificant values as determined by the investigator in conjunction with the Lilly physician.
- •[2]Laboratory values outside the ranges for the following:
- •Serum calcium 8.3 -10.6 mg/dL (conventional units)
- •2.07 - 2.64 mmol/L (SI units)
- •iPTH(1 84)b 11-72 pg/mL (conventional units)
- •1.2-7.6 pmol/L (SI units)
- •25 hydroxyvitamin D levels 20 to 61 ng/mL (conventional units)
- •50-153 pmol/mL (SI units)
- •aRanges specified for adults =18 years of age.
- •bRange using the Centaur Method.
- •[3]24-hour urine calcium higher than 300 mg/day.
- •[4]Abnormal thyroid function not corrected by therapy.
- •[5]Significantly impaired renal function. This is defined as:
- •-serum creatinine >2.0 mg/dL or 177 micromol/L; or
- •-measured or calculated creatinine clearance that, in the opinion of the investigator, indicates significant renal impairment.
- •[6]Significantly impaired hepatic function, defined as:
- •single transaminase (alanine transaminase [ALT], aspartate transaminase [AST], or gamma-glutamyl transpeptidase [GGT]) greater than 3 times the upper limit of normal (ULN); or
- •total bilirubin greater than 2.0 mg/dL (34 micromol/L).
- •[7]History of diseases other than postmenopausal osteoporosis that affect bone metabolism, such as Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hypoparathyroidism, hyperparathyroidism, and intestinal malabsorption.
- •[8]History of malignant neoplasms in the 5 years prior to randomization,
- •[9]History of nephrolithiasis or urolithiasis in the 2 years prior to randomization.
- •[10]Use of a pacemaker.
- •[11]Patients prone to bleeding with coagulopathies, such as hemophilia or thrombocytopenia.
- •[12]History of excessive consumption of alcohol or abuse of drugs in the 1 year prior to randomization, in the opinion of the investigator.
- •31 Prior participation in any other clinical trial studying or prior treatment with denosumab or strontium ranelate
研究者
相似试验
进行中（未招募）
不适用
2. fázisú vizsgálat a teriparatid borön át történo alkalmazásárólEUCTR2009-011883-12-HUElli Lilly and Company233
尚未招募
不适用
icotine replacement thrapy as a secondary prevention strategy in post-operative coronary bypass patientssmokingCardiovascular - Coronary heart diseaseACTRN12607000572460niversity of Adelaide30
招募中
不适用
Evaluation of clinical efficacy of transdermal Tulobuterol to the small airway dysfunction in patient with COPD.JPRN-UMIN000007148Kanazawa Medical University10
已完成
不适用
Evaluation of clinical efficacy of transdermal Tulobuterol to the small airway dysfunction in patient with COPD.JPRN-UMIN000006256Kanazawa Medical University10
进行中（未招募）
2 期
A trial of stimulating the vagus nerve at the ear for people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)Myalgic Encephalomyelitis (ME)Nervous System DiseasesISRCTN15931869niversity of Liverpool40